Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last 182.00 TWD
Change Today +4.00 / 2.25%
Volume 1.1M
4162 On Other Exchanges
Symbol
Exchange
Taiwan
As of 2:32 AM 07/29/15 All times are local (Market data is delayed by at least 15 minutes).

pharmaengine inc (4162) Snapshot

Open
181.00
Previous Close
178.00
Day High
185.50
Day Low
178.50
52 Week High
04/28/15 - 300.00
52 Week Low
07/28/15 - 169.00
Market Cap
18.5B
Average Volume 10 Days
1.5M
EPS TTM
1.01
Shares Outstanding
101.8M
EX-Date
06/30/15
P/E TM
180.4x
Dividend
1.00
Dividend Yield
0.55%
Current Stock Chart for PHARMAENGINE INC (4162)

Related News

No related news articles were found.

pharmaengine inc (4162) Related Businessweek News

No Related Businessweek News Found

pharmaengine inc (4162) Details

PharmaEngine, Inc., a biopharmaceutical company, is engaged in the development of drugs for the treatment of cancer and Asian prevalent diseases in Taiwan. The company develops, manufactures, and commercializes PEP02, a novel and stable nanoliposomal formulation of irinotecan, which has completed four Phase I studies and two Phase II studies for gastric and pancreatic cancers in Asia and Europe. It also develops PEP503, a crystalline hafnium oxide, which is in Phase I trial in France. PharmaEngine, Inc. has collaborations with Merrimack Pharmaceuticals, Inc.; Nanobiotix S.A.; and Guangzhou BeBetter Medicine Technology Co., Ltd. The company was founded in 2003 and is based in Taipei, Taiwan.

Founded in 2003

pharmaengine inc (4162) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

pharmaengine inc (4162) Key Developments

PharmaEngine Inc. Announces Filing of Drug Application of MM-398 (PEP02) to Taiwan FDA

PharmaEngine Inc. announced that a New Drug Application (NDA) has been submitted to the Taiwan Food and Drug Administration (TFDA) for MM-398 (irinotecan liposome injection, also known as nal-IRI) in patients with metastatic adenocarcinoma of the pancreas who have been previously treated with gemcitabine-based therapy. The filing of MM-398 to the TFDA follows the recent submissions of NDA and marketing authorization application (MAA) by its licensing partner, Merrimack Pharmaceuticals Inc. and its sublicensing partner, Baxter International's BioScience business to the US FDA and to the European Medicines Agency (EMA), respectively. The filing of MM-398 to the TFDA was supported by the positive data from a phase 3 study (NAPOLI-1) conducted in patients with metastatic pancreatic cancer who previously received gemcitabine-based therapy.

PharmaEngine Inc., Annual General Meeting, Jun 10, 2015

PharmaEngine Inc., Annual General Meeting, Jun 10, 2015.

Merrimack Pharmaceuticals and PharmaEngine Report Positive Phase III Results for MM-398 in Pancreatic Cancer

PharmaEngine and its partner Merrimack Pharmaceuticals have presented additional analyses from a global, randomised, open-label Phase III (NAPOLI-1) trial investigating the safety and efficacy of MM-398 (liposome irinotecan injection) in metastatic pancreatic cancer. The analyses of the trial lend further support to the positive top-line data that were presented in 2014 demonstrating a statistical increase in overall survival (OS) following treatment with MM-398 and 5-fluorouracil and leucovorin (5-FU/LV), with a hazard ratio of 0.67 (p=0.01) and a median OS of 6.1 months, compared with 4.2 months with 5-FU/LV alone. In the expanded analyses, the OS for MM-398 hazard ratio was 0.57 (p=0.0009) in the stratified analysis that accounts for pre-specified prognostic factors, while the analysis of the per protocol population, or those patients who received 80% of protocol-defined dose and remained on treatment for at least six weeks demonstrated more statistical improvement in median OS (8.9 months) compared with the control arm (5.1 months; p=0.0018). In addition, the trial revealed significant improvements in progression-free survival, objective response rate, and CA19-9 tumour market response following treatment with MM-398 compared with the control arm. The data were presented at the Gastrointestinal Cancers Symposium of the American Society of Clinical Oncology on 16 January 2015.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
4162:TT 182.00 TWD +4.00

4162 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 4162.
View Industry Companies
 

Industry Analysis

4162

Industry Average

Valuation 4162 Industry Range
Price/Earnings 100.0x
Price/Sales 77.6x
Price/Book 6.2x
Price/Cash Flow 176.6x
TEV/Sales 64.3x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PHARMAENGINE INC, please visit www.pharmaengine.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.